Cargando…

Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease

The SARS-CoV-2 coronavirus has led to a pandemic with millions of people affected. The present study finds that risk-factors for severe COVID-19 disease courses, i.e. male sex, older age and sedentary life style are associated with higher prostaglandin E2 (PGE2) serum levels in blood samples from un...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricke-Hoch, Melanie, Stelling, Elisabeth, Lasswitz, Lisa, Gunesch, Antonia P., Kasten, Martina, Zapatero-Belinchón, Francisco J., Brogden, Graham, Gerold, Gisa, Pietschmann, Thomas, Montiel, Virginie, Balligand, Jean-Luc, Facciotti, Federica, Hirsch, Emilio, Gausepohl, Thomas, Elbahesh, Husni, Rimmelzwaan, Guus F., Höfer, Anne, Kühnel, Mark P., Jonigk, Danny, Eigendorf, Julian, Tegtbur, Uwe, Mink, Lena, Scherr, Michaela, Illig, Thomas, Schambach, Axel, Pfeffer, Tobias J., Hilfiker, Andres, Haverich, Axel, Hilfiker-Kleiner, Denise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336874/
https://www.ncbi.nlm.nih.gov/pubmed/34347801
http://dx.doi.org/10.1371/journal.pone.0255335
_version_ 1783733394608226304
author Ricke-Hoch, Melanie
Stelling, Elisabeth
Lasswitz, Lisa
Gunesch, Antonia P.
Kasten, Martina
Zapatero-Belinchón, Francisco J.
Brogden, Graham
Gerold, Gisa
Pietschmann, Thomas
Montiel, Virginie
Balligand, Jean-Luc
Facciotti, Federica
Hirsch, Emilio
Gausepohl, Thomas
Elbahesh, Husni
Rimmelzwaan, Guus F.
Höfer, Anne
Kühnel, Mark P.
Jonigk, Danny
Eigendorf, Julian
Tegtbur, Uwe
Mink, Lena
Scherr, Michaela
Illig, Thomas
Schambach, Axel
Pfeffer, Tobias J.
Hilfiker, Andres
Haverich, Axel
Hilfiker-Kleiner, Denise
author_facet Ricke-Hoch, Melanie
Stelling, Elisabeth
Lasswitz, Lisa
Gunesch, Antonia P.
Kasten, Martina
Zapatero-Belinchón, Francisco J.
Brogden, Graham
Gerold, Gisa
Pietschmann, Thomas
Montiel, Virginie
Balligand, Jean-Luc
Facciotti, Federica
Hirsch, Emilio
Gausepohl, Thomas
Elbahesh, Husni
Rimmelzwaan, Guus F.
Höfer, Anne
Kühnel, Mark P.
Jonigk, Danny
Eigendorf, Julian
Tegtbur, Uwe
Mink, Lena
Scherr, Michaela
Illig, Thomas
Schambach, Axel
Pfeffer, Tobias J.
Hilfiker, Andres
Haverich, Axel
Hilfiker-Kleiner, Denise
author_sort Ricke-Hoch, Melanie
collection PubMed
description The SARS-CoV-2 coronavirus has led to a pandemic with millions of people affected. The present study finds that risk-factors for severe COVID-19 disease courses, i.e. male sex, older age and sedentary life style are associated with higher prostaglandin E2 (PGE2) serum levels in blood samples from unaffected subjects. In COVID-19 patients, PGE2 blood levels are markedly elevated and correlate positively with disease severity. SARS-CoV-2 induces PGE2 generation and secretion in infected lung epithelial cells by upregulating cyclo-oxygenase (COX)-2 and reducing the PG-degrading enzyme 15-hydroxyprostaglandin-dehydrogenase. Also living human precision cut lung slices (PCLS) infected with SARS-CoV-2 display upregulated COX-2. Regular exercise in aged individuals lowers PGE2 serum levels, which leads to increased Paired-Box-Protein-Pax-5 (PAX5) expression, a master regulator of B-cell survival, proliferation and differentiation also towards long lived memory B-cells, in human pre-B-cell lines. Moreover, PGE2 levels in serum of COVID-19 patients lowers the expression of PAX5 in human pre-B-cell lines. The PGE2 inhibitor Taxifolin reduces SARS-CoV-2-induced PGE2 production. In conclusion, SARS-CoV-2, male sex, old age, and sedentary life style increase PGE2 levels, which may reduce the early anti-viral defense as well as the development of immunity promoting severe disease courses and multiple infections. Regular exercise and Taxifolin treatment may reduce these risks and prevent severe disease courses.
format Online
Article
Text
id pubmed-8336874
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-83368742021-08-05 Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease Ricke-Hoch, Melanie Stelling, Elisabeth Lasswitz, Lisa Gunesch, Antonia P. Kasten, Martina Zapatero-Belinchón, Francisco J. Brogden, Graham Gerold, Gisa Pietschmann, Thomas Montiel, Virginie Balligand, Jean-Luc Facciotti, Federica Hirsch, Emilio Gausepohl, Thomas Elbahesh, Husni Rimmelzwaan, Guus F. Höfer, Anne Kühnel, Mark P. Jonigk, Danny Eigendorf, Julian Tegtbur, Uwe Mink, Lena Scherr, Michaela Illig, Thomas Schambach, Axel Pfeffer, Tobias J. Hilfiker, Andres Haverich, Axel Hilfiker-Kleiner, Denise PLoS One Research Article The SARS-CoV-2 coronavirus has led to a pandemic with millions of people affected. The present study finds that risk-factors for severe COVID-19 disease courses, i.e. male sex, older age and sedentary life style are associated with higher prostaglandin E2 (PGE2) serum levels in blood samples from unaffected subjects. In COVID-19 patients, PGE2 blood levels are markedly elevated and correlate positively with disease severity. SARS-CoV-2 induces PGE2 generation and secretion in infected lung epithelial cells by upregulating cyclo-oxygenase (COX)-2 and reducing the PG-degrading enzyme 15-hydroxyprostaglandin-dehydrogenase. Also living human precision cut lung slices (PCLS) infected with SARS-CoV-2 display upregulated COX-2. Regular exercise in aged individuals lowers PGE2 serum levels, which leads to increased Paired-Box-Protein-Pax-5 (PAX5) expression, a master regulator of B-cell survival, proliferation and differentiation also towards long lived memory B-cells, in human pre-B-cell lines. Moreover, PGE2 levels in serum of COVID-19 patients lowers the expression of PAX5 in human pre-B-cell lines. The PGE2 inhibitor Taxifolin reduces SARS-CoV-2-induced PGE2 production. In conclusion, SARS-CoV-2, male sex, old age, and sedentary life style increase PGE2 levels, which may reduce the early anti-viral defense as well as the development of immunity promoting severe disease courses and multiple infections. Regular exercise and Taxifolin treatment may reduce these risks and prevent severe disease courses. Public Library of Science 2021-08-04 /pmc/articles/PMC8336874/ /pubmed/34347801 http://dx.doi.org/10.1371/journal.pone.0255335 Text en © 2021 Ricke-Hoch et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ricke-Hoch, Melanie
Stelling, Elisabeth
Lasswitz, Lisa
Gunesch, Antonia P.
Kasten, Martina
Zapatero-Belinchón, Francisco J.
Brogden, Graham
Gerold, Gisa
Pietschmann, Thomas
Montiel, Virginie
Balligand, Jean-Luc
Facciotti, Federica
Hirsch, Emilio
Gausepohl, Thomas
Elbahesh, Husni
Rimmelzwaan, Guus F.
Höfer, Anne
Kühnel, Mark P.
Jonigk, Danny
Eigendorf, Julian
Tegtbur, Uwe
Mink, Lena
Scherr, Michaela
Illig, Thomas
Schambach, Axel
Pfeffer, Tobias J.
Hilfiker, Andres
Haverich, Axel
Hilfiker-Kleiner, Denise
Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
title Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
title_full Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
title_fullStr Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
title_full_unstemmed Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
title_short Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease
title_sort impaired immune response mediated by prostaglandin e2 promotes severe covid-19 disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336874/
https://www.ncbi.nlm.nih.gov/pubmed/34347801
http://dx.doi.org/10.1371/journal.pone.0255335
work_keys_str_mv AT rickehochmelanie impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT stellingelisabeth impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT lasswitzlisa impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT guneschantoniap impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT kastenmartina impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT zapaterobelinchonfranciscoj impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT brogdengraham impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT geroldgisa impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT pietschmannthomas impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT montielvirginie impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT balligandjeanluc impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT facciottifederica impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT hirschemilio impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT gausepohlthomas impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT elbaheshhusni impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT rimmelzwaanguusf impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT hoferanne impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT kuhnelmarkp impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT jonigkdanny impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT eigendorfjulian impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT tegtburuwe impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT minklena impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT scherrmichaela impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT illigthomas impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT schambachaxel impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT pfeffertobiasj impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT hilfikerandres impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT haverichaxel impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease
AT hilfikerkleinerdenise impairedimmuneresponsemediatedbyprostaglandine2promotesseverecovid19disease